![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Biosphere Medical (MM) | NASDAQ:BSMD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.38 | 0 | 01:00:00 |
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 19, 2010
BIOSPHERE MEDICAL, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware |
|
000-23678 |
|
04-3216867 |
(State or Other Jurisdiction of
|
|
(Commission File Number) |
|
(IRS Employer
|
1050 Hingham Street
|
|
|
|
02370 |
(Address of Principal Executive
|
|
|
|
(Zip Code) |
Registrants telephone number, including area code: (781) 681-7900
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
x Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On June 10, 2010, certain of the members of the Board of Directors of BioSphere Medical, Inc. (the Company) were named as defendants in a putative class action complaint, captioned Fessahaye v. Faleschini, et al. , C.A. No. 5553-CC, filed in the Court of Chancery of the State of Delaware. The action, purportedly brought on behalf of a class of the Companys stockholders, alleges that certain of the Companys directors purportedly breached their fiduciary duties in connection with the Companys proposed merger with Merit by failing to maximize shareholder value and obtain the best financial and other terms. The complaint includes a request for declaratory, injunctive and other equitable relief, including to enjoin the Company from consummating the merger with Merit, in addition to fees and costs. On July 19, 2010, plaintiff filed an amended complaint adding the Company as a defendant and further alleging that the Companys preliminary proxy statement fails to provide material information and provides materially misleading information relating to the proposed merger transaction. The Company believes that the claims are without merit and intends to defend the suit vigorously.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 23, 2010 |
BIOSPHERE MEDICAL, INC. |
|
|
|
|
|
|
|
|
By: |
/s/ Martin J. Joyce |
|
|
Martin J. Joyce |
|
|
Executive Vice President |
|
|
and Chief Financial Officer |
1 Year Biosphere Medical (MM) Chart |
1 Month Biosphere Medical (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions